Long-Term Monitoring and Quality of Life
At a Glance
For people with stable ITP, long-term care focuses on an individualized safe platelet target and quality of life rather than a normal count. A personal plan can reduce test anxiety, address fatigue, recognize clot symptoms, and guide care during infections or vaccines.
Once the initial crisis of an ITP diagnosis has passed and your platelet counts have reached a stable “hemostatic” level, the focus of your care shifts. Long-term management is less about the numbers and more about how you live your life, how you monitor your health, and how you manage the ongoing symptoms like fatigue [1][2].
Managing “Blood Test Anxiety”
Living with a chronic condition that is monitored through frequent lab work can take a significant psychological toll. Many patients experience what is informally called “platelet count anxiety”—a sense of dread or panic before a blood draw or while waiting for results [3].
- The Psychological Impact: Studies have shown that higher levels of anxiety are associated with a lower quality of life for people with ITP [3].
- Small Fluctuations: It is important to remember that platelet counts naturally fluctuate. A small drop (e.g., from 50,000 to 42,000) is often just a normal variation and does not necessarily mean your ITP is “worsening” [4].
- Goal-Oriented Monitoring: As you become clinically stable without changing treatments, you and your doctor can often extend the time between blood tests. Moving from weekly to monthly (or even quarterly) tests can significantly reduce the burden on your daily life [5]. However, never extend your monitoring independently. More frequent testing is required if you are starting or adjusting a TPO-receptor agonist, if you become pregnant, or if your counts are trending downward.
The Hidden Risk: Thrombosis
It may seem counterintuitive, but having a low platelet count does not automatically protect you from thrombosis (blood clots) [6][7]. In fact, people with ITP have a slightly higher risk of both arterial (e.g., heart attack or stroke) and venous (e.g., DVT or pulmonary embolism) blood clots than the general population [8][6].
- The “Double Risk”: The risk of a clot exists even when your platelet count is below 100,000 [6].
- Treatment Factors: Certain treatments, specifically TPO-RAs (like eltrombopag or romiplostim), can increase this risk, especially in patients who are older, smoke, or have other cardiovascular risk factors [9][10][11].
- Splenectomy: Patients who have had their spleen removed also carry a long-term increased risk of blood clots [12][13].
- Warning Signs: Seek emergency care immediately if you experience new one-sided leg swelling or pain, sudden shortness of breath or chest pain, or sudden neurological symptoms. Do not wait for a platelet test to act on these symptoms.
- Monitoring: This is why your doctor targets a “safe” count rather than a “normal” one; keeping the count very high with medication may unnecessarily increase your risk of a clot [14][15].
Infections, Vaccines, and Platelet “Flares”
Systemic challenges to your immune system—like a viral infection or a vaccination—can cause a temporary dip or surge in your platelet counts.
- COVID-19 Infection: About 18% to 30% of ITP patients see their counts drop during or shortly after a COVID-19 infection [16][17]. Most of these “flares” happen within the first two weeks of the infection [16].
- Vaccinations: Routine vaccination is generally recommended for people with ITP; do not skip or delay it without discussing a plan with your clinician. COVID-19 and other vaccines can cause a modest, temporary drop in platelets in about 14% of ITP patients [18]. A very small group may experience a more significant drop with bleeding symptoms, but these cases typically respond well to a short “rescue” treatment [19][20].
- Monitoring Plan: Routine pre- and post-vaccination checking is not required for every stable patient. Monitoring should be individualized according to your baseline count, recent stability, prior vaccine-related drops, and the specific vaccine or infection [18][16].
Living with Fatigue
Fatigue remains one of the most common and frustrating aspects of living with stable ITP, affecting more than half of all patients [21][22].
- Not Just “Tired”: ITP-related fatigue can feel like a heavy, persistent exhaustion that isn’t always fixed by sleep [21].
- Management: While raising your platelet count sometimes helps, fatigue can persist even when your numbers are “good” [22]. Do not assume fatigue is always from ITP. Management often involves a “shared decision-making” approach where you and your doctor investigate other causes—such as anemia from menstrual bleeding, thyroid disease, sleep problems, mood, or medication effects—before making lifestyle adjustments to help you safely return to your preferred activities [1][2].
Create a Personal Care Plan
To reduce anxiety and increase safety, create a personal care plan with your hematologist. Write down your usual platelet range, your current medications and doses, the date of your next blood test, contact information for your hematology clinic (including after-hours), and explicit instructions on what to do during an infection, active bleeding, or before a planned medical procedure.
Despite these challenges, many people with ITP live full, active lives. Once a stable routine is established, ITP often becomes a condition you “manage” in the background, rather than one that defines your daily existence.
Common questions in this guide
How often do I need platelet tests when my ITP is stable?
Does a small drop in my platelet count mean my ITP is getting worse?
Can ITP cause blood clots even when my platelet count is low?
When should I seek emergency help for possible blood clot symptoms?
Can an infection or vaccine make my ITP platelet count fall?
Why am I fatigued even though my platelet count is stable?
What should I include in a long-term ITP care plan?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on primary thrombocytopenia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How can we adjust my monitoring schedule to reduce 'blood test anxiety' while still keeping me safe?
- 2.Given my age and health history, what is my personal risk for a blood clot, and how does my treatment (like a TPO-RA) affect that?
- 3.If I get a viral infection or a vaccine, what is our specific plan for checking my platelet counts over the following two weeks?
- 4.Are there non-medication strategies or lifestyle adjustments we can explore to help manage my ITP-related fatigue?
- 5.Now that my counts are stable, are there activities I previously avoided that I can safely resume?
References
References (22)
- 1
Second-line therapies in immune thrombocytopenia.
Grace RF, Neunert C
Hematology. American Society of Hematology. Education Program 2016; (2016(1)):698-706 doi:10.1182/asheducation-2016.1.698.
PMID: 27913549 - 2
Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society.
Janssens A, Selleslag D, Depaus J, et al.
Acta clinica Belgica 2022; (77(2)):470-483 doi:10.1080/17843286.2021.1876310.
PMID: 33635747 - 3
Influence of Anxiety Level and Degree of Alexithymia on Quality of Life in Adult Patients With Primary Immune Thrombocytopenia.
Liang S, Wu T, Chai L, et al.
Actas espanolas de psiquiatria 2025; (53(6)):1274-1285 doi:10.62641/aep.v53i6.2026.
PMID: 41437748 - 4
The Effect of COVID-19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real-World Study in China.
Zhang Y, Yang L, Xu Z, Zhou X
EJHaem 2025; (6(2)):e70025 doi:10.1002/jha2.70025.
PMID: 40161870 - 5
American Society of Hematology 2019 guidelines for immune thrombocytopenia.
Neunert C, Terrell DR, Arnold DM, et al.
Blood advances 2019; (3(23)):3829-3866 doi:10.1182/bloodadvances.2019000966.
PMID: 31794604 - 6
Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia.
Adelborg K, Kristensen NR, Nørgaard M, et al.
Journal of thrombosis and haemostasis : JTH 2019; (17(6)):912-924 doi:10.1111/jth.14446.
PMID: 30933417 - 7
Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study.
Le Guenno G, Guieze R, Audia S, et al.
Internal medicine journal 2019; (49(9)):1154-1162 doi:10.1111/imj.14269.
PMID: 30816621 - 8
Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts.
Ekstrand C, Linder M, Baricault B, et al.
Thrombosis research 2019; (178()):124-131 doi:10.1016/j.thromres.2019.04.016.
PMID: 31026663 - 9
Incidence, Characteristics, and Management of Venous Thrombosis in Adult Patients With Immune Thrombocytopenia: Results From the Multicenter, Prospective Registry CARMEN-France.
Therme F, Viallard JF, Rueter M, et al.
American journal of hematology 2026; (101(3)):456-466 doi:10.1002/ajh.70192.
PMID: 41504071 - 10
Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag vs romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) cohort.
Zordan J, Zadro Y, Sommet A, et al.
Journal of thrombosis and haemostasis : JTH 2026; (24(7)):2567-2578 doi:10.1016/j.jtha.2026.04.002.
PMID: 41967713 - 11
The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP?
Saldanha A, Colella MP, Villaça PR, et al.
Thrombosis research 2024; (241()):109109 doi:10.1016/j.thromres.2024.109109.
PMID: 39137700 - 12
Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study.
Lafaurie M, Maquet J, Baricault B, et al.
British journal of haematology 2021; (195(3)):456-465 doi:10.1111/bjh.17709.
PMID: 34386974 - 13
Long-term complications of splenectomy in adult immune thrombocytopenia.
Thai LH, Mahévas M, Roudot-Thoraval F, et al.
Medicine 2016; (95(48)):e5098 doi:10.1097/MD.0000000000005098.
PMID: 27902585 - 14
Advances in Diagnosis and Treatments for Immune Thrombocytopenia.
Nomura S
Clinical medicine insights. Blood disorders 2016; (9()):15-22 doi:10.4137/CMBD.S39643.
PMID: 27441004 - 15
A Case of Cerebral Venous Sinus Thrombosis Following Eltrombopag in Immune Thrombocytopenia.
Raja T, Jesiah N, Mayurathan P, Kugathasan A
Cureus 2025; (17(11)):e96811 doi:10.7759/cureus.96811.
PMID: 41404254 - 16
The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset: A nationally representative, prospective, multicentre, observational study.
Fu H, Cai X, Cui L, et al.
Annals of hematology 2024; (103(5)):1549-1559 doi:10.1007/s00277-024-05720-0.
PMID: 38526649 - 17
Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study.
Chen Y, Liu J, Shao S, et al.
British journal of haematology 2024; (204(4)):1207-1218 doi:10.1111/bjh.19198.
PMID: 37967471 - 18
COVID-19 vaccination in patients with immune thrombocytopenia.
Visser C, Swinkels M, van Werkhoven ED, et al.
Blood advances 2022; (6(6)):1637-1644 doi:10.1182/bloodadvances.2021006379.
PMID: 34941989 - 19
Exacerbation of immune thrombocytopenia following COVID-19 vaccination.
Kuter DJ
British journal of haematology 2021; (195(3)):365-370 doi:10.1111/bjh.17645.
PMID: 34075578 - 20
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP.
Lee EJ, Beltrami-Moreira M, Al-Samkari H, et al.
Blood 2022; (139(10)):1564-1574 doi:10.1182/blood.2021013411.
PMID: 34587251 - 21
Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study.
González-López TJ, Alperovich G, Burillo E, et al.
TH open : companion journal to thrombosis and haemostasis 2024; (8(3)):e252-e265 doi:10.1055/a-2336-1062.
PMID: 38983689 - 22
Epidemiology and Clinical Manifestations of Immune Thrombocytopenia.
Kohli R, Chaturvedi S
Hamostaseologie 2019; (39(3)):238-249 doi:10.1055/s-0039-1683416.
PMID: 30868551
This page is for informational purposes only and does not constitute medical advice. Your hematologist should tailor monitoring, treatment, and emergency guidance to your platelet counts, symptoms, and health history.